Ank Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.99 M
- Revenue Growth -56.35%
- Profit Growth 37.97%
- Ebitda -16.97%
- Net Worth -7.02%
- Total Assets 5.41%
About Ank Pharma
Ank Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 July 2005 and has a history of 19 years and seven months. Its registered office is in Boisar, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹7.99 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Kokilaben Patel, Natvarbhai Patel, Ankit Patel, and One other member serve as directors at the Company.
Company Details
-
Location
Boisar, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2005PTC154557
-
Company No.
154557
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Jul 2005
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Ank Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kokilaben Patel
|
Director | 07-Jul-2005 | Current |
|
Natvarbhai Patel
|
Director | 07-Jul-2005 | Current |
|
Ankit Patel
|
Director | 22-May-2019 | Current |
|
Ruchi Patel
|
Director | 22-May-2019 | Current |
Financial Performance of Ank Pharma.
Ank Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 56.35% decrease. The company also saw a substantial improvement in profitability, with a 37.97% increase in profit. The company's net worth dipped by a decrease of 7.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ank Pharma?
In 2023, Ank Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹7.99 M
Charges Breakdown by Lending Institutions
- The Saraswat Cooperative Bank Ltd : 0.80 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Jun 2010 | The Saraswat Cooperative Bank Ltd | ₹7.99 M | Satisfied |
How Many Employees Work at Ank Pharma?
Unlock and access historical data on people associated with Ank Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ank Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ank Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.